A Toolkit for Single-Nucleus Characterization of Glioblastoma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Genomics

Background:

• Glioblastoma (GBM) is a lethal primary adult brain tumor characterized by a heterogeneous ecosystem and an immunosuppressive tumor microenvironment (TME).
• High-throughput single-cell omics, including single-cell RNA sequencing (scRNA-seq) and single-nucleus RNA sequencing (snRNA-seq), are powerful tools for dissecting cellular heterogeneity and interactions within the GBM ecosystem.
• snRNA-seq is particularly valuable for analyzing frozen samples and challenging tissues like brain tumors, offering an alternative to scRNA-seq.

Purpose of the Study:

• To develop and provide a detailed toolkit of optimized protocols for preparing high-quality single nuclei from clinical glioblastoma specimens and patient-derived cell lines.
• To enable streamlined and efficient single-nucleus preparation for subsequent snRNA-seq characterization of GBM.
• To facilitate a deeper understanding of the cellular and molecular complexity of the glioblastoma ecosystem.

Main Methods:

• Development of detailed protocols for nucleus isolation from GBM specimens and cell lines.
• Implementation of standardized procedures for nucleus counting and quality control.
• Adaptation of methods for compatibility with frozen samples and difficult-to-dissociate tissues.

Main Results:

• A comprehensive toolkit of optimized protocols for single-nucleus preparation from glioblastoma samples has been established.
• The protocols ensure high-quality nuclei suitable for downstream snRNA-seq analysis.
• The toolkit addresses challenges associated with processing clinical GBM specimens and patient-derived cell lines.

Conclusions:

• The provided toolkit enables efficient and reliable single-nucleus preparation for snRNA-seq in glioblastoma research.
• This methodology is crucial for deconvoluting the cellular heterogeneity and molecular interactions within the complex GBM tumor microenvironment.
• Facilitating high-quality snRNA-seq data acquisition will advance our understanding and therapeutic strategies for glioblastoma.